InterCure 過去の業績
過去 基準チェック /06
InterCure has been growing earnings at an average annual rate of 1%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 45.1% per year.
主要情報
1.0%
収益成長率
10.7%
EPS成長率
| Pharmaceuticals 業界の成長 | 35.1% |
| 収益成長率 | 45.1% |
| 株主資本利益率 | -14.6% |
| ネット・マージン | -24.1% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well
Feb 16
What InterCure Ltd.'s (TLV:INCR) P/E Is Not Telling You
Sep 19Here's Why InterCure (TLV:INCR) Can Manage Its Debt Responsibly
Aug 22InterCure (TLV:INCR) Seems To Use Debt Quite Sensibly
Feb 14These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well
Sep 11What Percentage Of InterCure Ltd (TLV:INCR) Shares Do Insiders Own?
Mar 08Shareholders Are Raving About How The InterCure (TLV:INCR) Share Price Increased 936%
Jan 12Is InterCure (TLV:INCR) Using Debt Sensibly?
Dec 04
収支内訳
InterCure の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 273 | -66 | 93 | 0 |
| 31 Mar 24 | 312 | -61 | 96 | 0 |
| 31 Dec 23 | 356 | -62 | 98 | 0 |
| 30 Sep 23 | 388 | -20 | 103 | 0 |
| 30 Jun 23 | 415 | 21 | 110 | 1 |
| 31 Mar 23 | 408 | 32 | 109 | 1 |
| 31 Dec 22 | 389 | 45 | 102 | 1 |
| 30 Sep 22 | 363 | 33 | 96 | 1 |
| 30 Jun 22 | 324 | 24 | 80 | 1 |
| 31 Mar 22 | 274 | 15 | 67 | 1 |
| 31 Dec 21 | 220 | 5 | 57 | 1 |
| 30 Sep 21 | 167 | 17 | 43 | 1 |
| 30 Jun 21 | 128 | 20 | 35 | 2 |
| 31 Mar 21 | 94 | 13 | 30 | 2 |
| 31 Dec 20 | 65 | -37 | 27 | 2 |
| 30 Sep 20 | 40 | -63 | 26 | 2 |
| 30 Jun 20 | 20 | -80 | 32 | 2 |
| 31 Mar 20 | 11 | -91 | 41 | 2 |
| 31 Dec 19 | 9 | -6 | 83 | 2 |
| 30 Sep 19 | 7 | 7 | 81 | 1 |
| 30 Jun 19 | 5 | 18 | 72 | 0 |
| 31 Mar 19 | 2 | 27 | 58 | 0 |
| 31 Dec 18 | 0 | -13 | 10 | 0 |
| 30 Sep 18 | 0 | -10 | 5 | 0 |
| 30 Jun 18 | 0 | -8 | 1 | 0 |
| 31 Mar 18 | 0 | -7 | 1 | 0 |
| 31 Dec 17 | 0 | -6 | 1 | 0 |
| 30 Sep 17 | 0 | -4 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | 0 | 1 | 0 |
| 30 Sep 16 | 0 | 0 | 2 | 0 |
| 30 Jun 16 | 0 | -1 | 2 | 0 |
| 31 Mar 16 | 1 | 0 | 2 | 0 |
| 31 Dec 15 | 1 | -2 | 2 | 0 |
| 30 Sep 15 | 2 | -1 | 3 | 0 |
| 30 Jun 15 | 3 | -2 | 3 | 0 |
| 31 Mar 15 | 4 | -4 | 4 | 0 |
| 31 Dec 14 | 6 | -4 | 6 | 0 |
| 30 Sep 14 | 7 | -5 | 6 | 0 |
| 30 Jun 14 | 7 | -5 | 6 | 0 |
| 31 Mar 14 | 8 | -6 | 7 | 0 |
| 31 Dec 13 | 8 | -7 | 8 | 0 |
質の高い収益: INCR is currently unprofitable.
利益率の向上: INCR is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: INCR is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.
成長の加速: Unable to compare INCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: INCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
株主資本利益率
高いROE: INCR has a negative Return on Equity (-14.58%), as it is currently unprofitable.